{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:50:55Z","timestamp":1759402255793},"reference-count":30,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Our goal in the present work was to characterize the multiple steps involved in overcoming the anergy that exists in tumor hosts to tumor-associated antigen (TAA). Our studies showed that the subcutaneous injection of the Ad-sig-TAA\/ecdCD40L vector resulted in secretion of the TAA\/ecdCD40L protein for at least 10 days from infected cells. Binding of the TAA\/ecdCD40L protein to dendritic cells (DCs) resulted in the induction of CCR-7 chemokine receptor expression and cytokine release. This was followed by migration of the DCs to regional lymph nodes. Tetramer staining, enzyme-linked immunospot (ELISPOT) assay, and cytotoxicity assay all showed that the Ad-sig-TAA\/ecdCD40L vector increased the levels of splenic CD8+ T cells specific for the 2 TAAs (human MUC1 [hMUC1] and HPV E7) tested. Vaccination with the Ad-sighMUC1\/ecdCD40L vector suppressed the growth of hMUC1 antigen-positive tumor cells in 100% of the test mice that were previously anergic to the hMUC1 antigen. These data suggest that Ad-sig-TAA-ecd\/ecdCD40L vector injections may be of value in treating the many epithelial malignancies in which TAA-like hMUC1 is overexpressed. (Blood. 2004;104:2704-2713)<\/jats:p>","DOI":"10.1182\/blood-2003-12-4319","type":"journal-article","created":{"date-parts":[[2004,7,7]],"date-time":"2004-07-07T01:03:13Z","timestamp":1089162193000},"page":"2704-2713","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens"],"prefix":"10.1182","volume":"104","author":[{"given":"Yucheng","family":"Tang","sequence":"first","affiliation":[{"name":"From the Sidney Kimmel Cancer Center, San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Zhang","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Cancer Center, San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Cancer Center, San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Akbulut","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Cancer Center, San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Maynard","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Cancer Center, San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis-Jean","family":"Linton","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Cancer Center, San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Deisseroth","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Cancer Center, San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021222395690200_REF1","doi-asserted-by":"crossref","unstructured":"Zhang L, Tang YC, Akbulut H, Zelterman D, Linton PJ, Deisseroth AB. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen\/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci U S A. 2003;100: 15101-15106.","DOI":"10.1073\/pnas.2135379100"},{"key":"2020021222395690200_REF2","doi-asserted-by":"crossref","unstructured":"Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol. 1994;12: 991-993.","DOI":"10.1146\/annurev.iy.12.040194.005015"},{"key":"2020021222395690200_REF3","doi-asserted-by":"crossref","unstructured":"Wurtzen PA, Nissen MH, Claesson MH. Maturation of dendritic cells by recombinant human CD40L-trimer leads to a homogeneous cell population with enhanced surface marker expression and increased cytokine production. Scand J Immunol. 2001;53: 579-587.","DOI":"10.1046\/j.1365-3083.2001.00910.x"},{"key":"2020021222395690200_REF4","doi-asserted-by":"crossref","unstructured":"Grewal I, Flavell R. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16: 111-135.","DOI":"10.1146\/annurev.immunol.16.1.111"},{"key":"2020021222395690200_REF5","doi-asserted-by":"crossref","unstructured":"Bennett S, Carbone F, Karamalis F, Flavell R, Miller J, Heath W. Help for cytotoxic T-cell responses are mediated by CD40 signaling. Nature. 1998;393: 478-480.","DOI":"10.1038\/30996"},{"key":"2020021222395690200_REF6","doi-asserted-by":"crossref","unstructured":"Schoenberger S, Toes RE, van der Voort EI, Offringa R, Melief C. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393: 480-483.","DOI":"10.1038\/31002"},{"key":"2020021222395690200_REF7","doi-asserted-by":"crossref","unstructured":"Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18: 767-811.","DOI":"10.1146\/annurev.immunol.18.1.767"},{"key":"2020021222395690200_REF8","doi-asserted-by":"crossref","unstructured":"Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med. 1997;186: 65-70.","DOI":"10.1084\/jem.186.1.65"},{"key":"2020021222395690200_REF9","doi-asserted-by":"crossref","unstructured":"Schuurhuis DH, Laban S, Toes RE, et al. Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med. 2000;192: 145-150.","DOI":"10.1084\/jem.192.1.145"},{"key":"2020021222395690200_REF10","doi-asserted-by":"crossref","unstructured":"Fanslow WC, Srinivasan S, Paxton R, Gibson MG, Spriggs MK, Armitage RJ. Structural characteristics of CD40 ligand that determine biological function. Semin Immunol. 1994:6: 267-278.","DOI":"10.1006\/smim.1994.1035"},{"key":"2020021222395690200_REF11","doi-asserted-by":"crossref","unstructured":"Tuting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or \u201cself\u201d antigens induce antitumor immunity in vivo. Eur J Immunol. 1997;27: 2702-2307.","DOI":"10.1002\/eji.1830271033"},{"key":"2020021222395690200_REF12","doi-asserted-by":"crossref","unstructured":"Fong L, Brockstedt D, Benike C Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol. 2001;166: 4254-4259.","DOI":"10.4049\/jimmunol.166.6.4254"},{"key":"2020021222395690200_REF13","doi-asserted-by":"crossref","unstructured":"Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4: 225-234.","DOI":"10.1038\/ni889"},{"key":"2020021222395690200_REF14","doi-asserted-by":"crossref","unstructured":"Xiang R, Primus FJ, Ruehlmnn JM, et al. Dual function DNA vaccine encoding carcinoembryonic antigen and CD40L trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol. 2001;167: 4560-4565.","DOI":"10.4049\/jimmunol.167.8.4560"},{"key":"2020021222395690200_REF15","doi-asserted-by":"crossref","unstructured":"Karpuses M, Hsu YM, Wang JH, et al. 2A crystal structure of an extracellular fragment of human CD40 ligand. Structure. 1995;3: 1031-1039.","DOI":"10.1016\/S0969-2126(01)00239-8"},{"key":"2020021222395690200_REF16","doi-asserted-by":"crossref","unstructured":"Kaplan JM, Yu Q, Piraino ST, et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol. 1999;163: 699-707.","DOI":"10.4049\/jimmunol.163.2.699"},{"key":"2020021222395690200_REF17","doi-asserted-by":"crossref","unstructured":"Berry JM, Palefsky JM. A review of human papillomavirus vaccines: from basic science to clinical trials. Frontiers Biosci. 2003;8: 333-345.","DOI":"10.2741\/1003"},{"key":"2020021222395690200_REF18","unstructured":"Liu W, Gao F, Zhao K, et al. Modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumor activity. Virology. 2002;15: 301-343."},{"key":"2020021222395690200_REF19","unstructured":"Kim TY, Myoung HJ, Kim JH, et al. Both E7 and CpG-oligodeoxynucleotides are required for protective immunity against challenge with human papillomavirus 16 (E6\/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res. 2003;63: 2393-2398."},{"key":"2020021222395690200_REF20","doi-asserted-by":"crossref","unstructured":"Hu G, Liu W, Mendelsohn J, Ellis L, Radinsky R, Deisseroth AB. High epidermal growth factor-receptor levels induced by the human papilloma viruss E6\/E7 proteins lead to unregulated growth in cervical carcinoma cells. J Natl Cancer Inst. 1997;89: 1271-1277.","DOI":"10.1093\/jnci\/89.17.1271"},{"key":"2020021222395690200_REF21","doi-asserted-by":"crossref","unstructured":"Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J. 2000;50: 7-33.","DOI":"10.3322\/canjclin.50.1.7"},{"key":"2020021222395690200_REF22","doi-asserted-by":"crossref","unstructured":"Ren J, Li Y, Kufe D. Protein kinase C delta regulates function of the DF3\/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem. 2002;277: 17616-17622.","DOI":"10.1074\/jbc.M200436200"},{"key":"2020021222395690200_REF23","doi-asserted-by":"crossref","unstructured":"Kontani K, Taguchi O, Narita T, et al. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer. 2001;84: 1258-1264.","DOI":"10.1054\/bjoc.2000.1744"},{"key":"2020021222395690200_REF24","unstructured":"Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 1998;58: 315-321."},{"key":"2020021222395690200_REF25","doi-asserted-by":"crossref","unstructured":"He TZ, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein BA. Simplified system for generating recombinant adenovirus. Proc Natl Acad Sci U S A. 1998;95: 2509-2514.","DOI":"10.1073\/pnas.95.5.2509"},{"key":"2020021222395690200_REF26","doi-asserted-by":"crossref","unstructured":"Parlato S, Santini SM, Lapenta C, et al. Expression of CCR-7, MIP-3 beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood. 2001;98: 3022-3029.","DOI":"10.1182\/blood.V98.10.3022"},{"key":"2020021222395690200_REF27","doi-asserted-by":"crossref","unstructured":"Rininsland FH, Helms T, Asaad RJ, Boehm BO, Tary-Lehmann M. Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Methods. 2000;240: 143-155.","DOI":"10.1016\/S0022-1759(00)00191-5"},{"key":"2020021222395690200_REF28","doi-asserted-by":"crossref","unstructured":"Ohlen C, Kalos M, Cheng LE, et al. CD8+ T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med. 2002;195: 1407-1418.","DOI":"10.1084\/jem.20011063"},{"key":"2020021222395690200_REF29","unstructured":"Gallichan WS, Rosenthal KLT. Cells home to tissue of body in which the lymph nodes are located in which they were originally activated. J Exp Med. 1996;184: 1879-1890."},{"key":"2020021222395690200_REF30","doi-asserted-by":"crossref","unstructured":"Zhang L, Akbulut H, Tang Y, et al. Adenoviral vectors with E1A regulated by tumor specific promoters are cytolytic for breast cancer and melanoma. Mol Ther. 2002: 6386-6393.","DOI":"10.1006\/mthe.2002.0680"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/9\/2704\/1702728\/zh802104002704.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/9\/2704\/1702728\/zh802104002704.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T23:17:57Z","timestamp":1682723877000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/9\/2704\/19406\/Multistep-process-through-which-adenoviral-vector"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,1]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,11,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-12-4319","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,1]]}}}